Lv2
150 积分 2023-12-23 加入
[Current status and prospects for screening early-stage hepatocellular carcinoma]
2天前
已完结
Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma
2天前
已完结
血管介入治疗联合系统治疗在不可切除肝细胞癌中的研究进展
2天前
已完结
Therapeutic options in hepatocellular carcinoma: a comprehensive review
3天前
已完结
Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis
6个月前
已完结
Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study
6个月前
已完结
The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in China: A retrospective, real-world study
6个月前
已关闭
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
6个月前
已完结
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
6个月前
已完结
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma
6个月前
已关闭
皖公网安备34019202002308
